SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

What are the exact molecular mechanisms underlying the bidirectional pathogenic loop between GCase dysfunction and α-synuclein pathology?

OPEN

The abstract describes a vicious cycle where GCase loss-of-function impairs α-synuclein degradation, while α-synuclein pathology inhibits GCase function, but states these mechanisms are not fully elucidated. Understanding this bidirectional relationship is critical for developing targeted therapeutics that could break this pathogenic cycle. Gap type: open_question Source paper: [GBA mutations and Parkinson's disease]. (2018, Sheng li xue bao : [Acta physiologica Sinica], PMID:29926071)

Priority: 0.85 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What are the exact molecular mechanisms underlying the bidirectional pathogenic loop between GCase dysfunction and α-synuclein pathology? is a 0.85 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What are the exact molecular mechanisms underlying the bidirectional pathogenic loop between GCase dysfunction and α-synuclein pathology? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (8)

TRIP12→GCaseGCase→protein aggregationGCase→lysosomal_dysfunctionGCase→mitochondrial_dysfunctionGCase→alpha_synuclein_aggregation
▸ Show 3 more

biomarker for (1)

GCase→alzheimer_disease

causes (1)

GCase→oxidative_stress

contributes to (6)

GCase→alpha_synuclein_aggregationGCase→lysosomal_dysfunctionGCase→mitochondrial_dysfunctionGCase→protein aggregationGCase→oxidative stress
▸ Show 1 more

degrades (1)

TRIP12→GCase

expresses (1)

GBA1→GCase

implicated in (2)

GCase→Gaucher diseaseGCase→Parkinson's_disease

increases risk (1)

GCase→parkinsons_disease

inhibits (4)

LPC→GCaseGCase→alpha_synuclein_aggregationGCase→mitochondrial_dysfunctionGCase→protein aggregation

interacts with (5)

TRIP12→GCaseGCase→alpha_synuclein_aggregationGCase→HSP70HSP70→GCaseGCase→TFEB

involved in (10)

GCase→lysosomal_functionGCase→alpha_synuclein_aggregationGCase→lysosomal_dysfunctionGCase→lysosomal_clearanceGCase→autophagy
▸ Show 5 more

mediates (2)

GCase→lysosomal_clearanceGCase→lysosomal_protein_degradation

modulates (8)

COMMD3→GCaseGCase→energy metabolismHDAC3 inhibition→GCaseGCase→protein_aggregationsmall molecule chaperones→GCase
▸ Show 3 more
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps